Physician profile

Khalil Kamar

Hematology & Oncology · Brewer, ME

NPI 1750801312

$900.07

in general payments reported to CMS, 2019-2025

9 companies · none reported in 2025

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$748.59

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
E.R. Squibb & Sons, L.L.C. $391.07 2023 Opdivo
Astrazeneca Pharmaceuticals LP $130.77 2023 Imfinzi
Janssen Scientific Affairs, LLC $65.88 2024 Erleada, Balversa
Kyowa Kirin, INC. $53.17 2023 Poteligeo
Amgen INC. $39.88 2022-2023 Xgeva, Vectibix, Nplate
Pfizer INC. $33.34 2024
Genzyme Corporation $22.75 2023
Bayer Healthcare Pharmaceuticals INC. $19.88 2023
Array Biopharma INC $18.33 2023 Comirnaty, Mektovi, Paxlovid

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Khalil Kamar

$900.07

in general payments reported 2019-2025

Years
2022-2024
Top company
E.R. Squibb & Sons, L.L.C.

https://glasscript.com/doctor/11459499/khalil-kamar

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.